|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early Her2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial显示文摘 | Gianni L Pienkowski T Im YH | 2012 | Lancet Oncol2012，13，1： | 1 |
| 2 | Phase m study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial显示文摘 | Eiermann W Pienkowski T Crown J | 2011 | J Clin Oncol2011，29，： | 1 |
| 3 | Efficacy and safety of neoadju-vant pertuzumab and trastuzumab in women with locally advanced,in-flammatory,or early HER2-positive breast cancer(NeoSphere):a ran-domised multicentre,open-label,phase 2 trial显示文摘 | Gianni L Pienkowski T Im YH | | 0，，： | 1 |
| 4 | Predictive value of HER-2 receptor,P53,bcl-2 and bax proteins, MIB- 1 antibody, estrogen and progesterone receptor expression in breast cancer patients receiving adjuvant tamoxifen显示文摘 | Pienkowski T Olszewski W Kraszewska E | 2002 | Eur J Cancer2002，38，： | 1 |
| 5 | Efficacy and safety of neoad-juvant pertuzumab and trastuzumab in women with locally ad-vanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial显示文摘 | Gianni L Pienkowski T Im YH | 2012 | Lan-cet Oncol2012，13，1： | 1 |
| 6 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial显示文摘 | Gianni L Pienkowski T Im YH | 2012 | Lancet Oncol2012，13，1： | 1 |
| 7 | Doxorubiein and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with advanced breast cancer: long-term analysis of the previously published trial 显示文摘 | Jassem J Pienkowski T Pluzanska A | 2009 | Onkologie2009，32，89： | 1 |
| 8 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer (NeoSphere):a randomised multicentre,open-label,phase 2 trial显示文摘 | Gianni L Pienkowski T Im YH | | 0，，01： | 1 |
| 9 | Efficacy and safety of neoadju- vant pertuzumab and trastuzumab in women with locally advanced,in- flammatory, or early her2-positive breast cancer ( neosphere ) : A ran- domised muhicentre, open-label, phase 2 trial 显示文摘 | Gianni L Pienkowski T Im YH | 2012 | Lancet Oncol2012，13，1： | 1 |
| 10 | A phase Ⅲ randomized trial comparing docetaxel in combination with doxorubiein and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her 2/neu negative axillary lymph node positive early breast cancer显示文摘 | Eiermann W Pienkowski T Crown J | 2009 | Cancer Res2009，77，： | 1 |
| 11 | Adjuvant docetaxel for node-positive breast cancer显示文摘 | Martin M Pienkowski T Mackey G | 2005 | N Engl J Med2005，352，18： | 1 |
| 12 | TAC improves disease free survival and overall survival over FAC in node positive early breast cancer patients,BCIRG001 : 55 months follow-up 显示文摘 | Martin M Pienkowski T Mackey J | 2003 | Breast Cancer Res Treat2003，82，1： | 1 |
| 13 | Efficacy and safety of neoad-juvant pertuzumab and trastuzumab in women with locally ad-vanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial显示文摘 | Gianni L Pienkowski T Im YH | 2012 | Lan-cet Oncol2012，13，1： | 1 |
| 14 | BCIRG 005 main efficacy analysis: a phase Ⅲ randomized trial comparing do cetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubiein and eyelophosphamlde followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer 显示文摘 | Eiermann W Pienkowski T Crown J | 2009 | Cancer Res2009，6977，： | 1 |
| 15 | Phase Ⅲ trial comparing TAC with FAC in the adjuvant treatment of node positive breast cancer patients: interim analysis显示文摘 | Nabholtz J M Pienkowski T Maekey J | 2002 | ASCO2002，，： | 1 |
| 16 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women withlocally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere) : a randomised multicentre, open - label, phase 2 trial显示文摘 | GIANNI L PIENKOWSKI T IM YH | 2012 | Lancet Oncol2012，13，1： | 1 |
| 17 | Doxorubicin and paclitaxel versus fiuorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase Ⅲmulticenter trial 显示文摘 | Jassem J Pienkowski T Pluzanska A | 2001 | J Clin Oncol2001，19，6： | 1 |
| 18 | Long-term survival in primary breast cancer:correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy显示文摘 | Chrapusta SJ Giermek J Pienkowski T | 2004 | Med Sci Monit2004，10，10： | 1 |
| 19 | Adjuvant docetaxel, doxorubi- cin,and cyclophosphamide in node -positive breast cancer: 10 - year follow - up of the phase 3 randomised BCIRG 001 trial 显示文摘 | Mackey JR Martin M Pienkowski T | 2013 | Lancet Onco12013，14，1： | 1 |
| 20 | Obervations of effects of partial vernalization in winter rape plants grafted onto generative stock显示文摘 | Filek W Pienkowski S Dubert F | 1986 | Journal of Agronomy and Crop Science-Zeitschrift Fur Acker Und Pflanzenbau1986，156，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员